Elevance Health’s first quarter was shaped by disciplined execution across its core businesses, with management highlighting both favorable claims experience and pronounced seasonality in the Individual ACA segment as contributors to outperformance. CEO Gail Boudreaux pointed to early evidence of cost containment in Medicaid, improved clinical outcomes through Carelon, and a more pronounced shift toward bronze ACA plans as key factors. Management emphasized that embedding AI across workflows and proactive clinical interventions are creating measurable efficiency gains and supporting more consistent results.
Is now the time to buy ELV? Find out in our full research report (it’s free for active Edge members).
Elevance Health (ELV) Q1 CY2026 Highlights:
- Revenue: $49.49 billion vs analyst estimates of $48.33 billion (1.5% year-on-year growth, 2.4% beat)
- Adjusted EPS: $12.58 vs analyst estimates of $10.81 (16.4% beat)
- Adjusted EBITDA: $4.08 billion vs analyst estimates of $3.73 billion (8.2% margin, 9.5% beat)
- Management raised its full-year Adjusted EPS guidance to $26.75 at the midpoint, a 4.9% increase
- Operating Margin: 5.4%, down from 6.4% in the same quarter last year
- Customers: 45.42 million, up from 45.23 million in the previous quarter
- Market Capitalization: $78.77 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Elevance Health’s Q1 Earnings Call
-
Albert Rice (UBS) asked about trends in the commercial employer market and PBM selling season. CEO Gail Boudreaux emphasized strong early employer interest in affordability and integrated AI capabilities, while CFO Mark Kaye highlighted Carelon Rx’s national account wins and growing demand for integrated pharmacy models.
-
Stephen Baxter (Wells Fargo) questioned cost trend moderation in Medicare versus Medicaid. Boudreaux described solid execution across both lines, emphasizing early traction from utilization management and site-of-care optimization.
-
Justin Lake (Wolfe Research) pressed on Medicaid membership declines and risk pool acuity. Kaye explained that guidance already reflects high single-digit declines and that the timing of state eligibility reviews could shift pressures later in the year.
-
Lisa Gill (JPMorgan) inquired about Carelon margins and regulatory changes. Kaye stated that first-quarter margins matched expectations and described the company’s transparency-based PBM model as aligned with federal trends.
-
Erin Wilson Wright (Morgan Stanley) sought quantification of AI-related efficiency gains. Boudreaux detailed over $1 billion in digital investments and noted widespread adoption of AI-enabled tools among both members and associates.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be monitoring (1) the effectiveness and measurable outcomes of AI and automation initiatives across the enterprise, (2) progress in expanding Carelon’s risk-based care models and their impact on clinical outcomes, and (3) trends in Medicaid membership and rate negotiations with state partners. Continued execution on ACA product mix optimization and commercial client retention will also be important markers for tracking Elevance Health’s performance trajectory.
Elevance Health currently trades at $361.06, up from $328.11 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
